Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Insmed Incorporated clinical trials
The registry lists 52 studies whose lead sponsor is Insmed Incorporated or one of 1 company grouped under it. 9 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 20, 2026.
Keep track of what changes. Save the Insmed Incorporated studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesRegistry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Insmed Incorporated.
- Insmed Incorporated50 studiesSame company
Something wrong?
- Insmed Gene Therapy LLC2 studies →Subsidiary
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 50 of 52. Browse all 52 →
- An Expanded Access Study to Assess Treprostinil Palmitil Inhalation Powder (TPIP) for Participants With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)AvailableNCT06939647
- Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)RecruitingNCT07179380Phase 3
- A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)RecruitingNCT07481981Phase 3
- A Study to Assess the Potential CYP3A Induction Effect of Brensocatib on the Pharmacokinetics (PK) of Midazolam in Healthy ParticipantsNot yet recruitingNCT07859007Phase 1
- A Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of INS1033 in Healthy ParticipantsRecruitingNCT07765706Phase 1
- A Study to Investigate the Safety and Pharmacodynamics of a Single Intrathecal Injection (IT) of INS1202 in Participants With Amyotrophic Lateral Sclerosis (ALS)RecruitingNCT07290062Phase 1
Sponsor listed in the registry: Insmed Gene Therapy LLC
- A Study to Evaluate the Pharmacokinetics (PK) and Safety of a Single Dose of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Normal Hepatic Function and Participants With Hepatic ImpairmentRecruitingNCT07643155Phase 1
- A Study to Assess the Efficacy and Safety of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Progressive Pulmonary Fibrosis (PPF)Not yet recruitingNCT07805785Phase 3
- An Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)RecruitingNCT07234032Phase 3
- An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Arterial Hypertension (PAH)Active, not recruitingNCT05649748Phase 2/3
- A Study of the Efficacy and Safety of Brensocatib in Participants With Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP)CompletedNCT06013241Phase 2
- A Study to Investigate the Safety and Biodistribution of a Single Intrathecal (IT) Injection of INS1201 in Ambulatory Males With Duchenne Muscular Dystrophy (DMD)Active, not recruitingNCT06817382Phase 1
Sponsor listed in the registry: Insmed Gene Therapy LLC
- Phase 2a Study of Efficacy and Safety of OpSCF in Moderate to Severe AD (Atopic Dermatitis)CompletedNCT06101823Phase 2
- A Study of the Efficacy and Safety of Brensocatib in Adults With Moderate to Severe Hidradenitis Suppurativa (HS)TerminatedNCT06685835Phase 2
- An Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) for Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)CompletedNCT05649722Phase 2/3
- A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial HypertensionCompletedNCT05147805Phase 2
- A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Brensocatib Tablets in Adults With Cystic FibrosisCompletedNCT05090904Phase 2
- Study to Evaluate ALIS (Amikacin Liposome Inhalation Suspension) in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium ComplexCompletedNCT04677569Phase 3
- A Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib in Participants With Non-Cystic Fibrosis BronchiectasisCompletedNCT04594369Phase 3
- A Study to Assess the Relative Bioavailability After a Single Inhalation Administration of Treprostinil Palmitil Inhalation Powder (TPIP) Formulation 2 (F2) to TPIP Formulation 3 (F3) in Healthy ParticipantsCompletedNCT07102316Phase 1
- An Expanded Access Study to Assess Brensocatib for Participants With Non-Cystic Fibrosis BronchiectasisApproved for marketingNCT05344508
- A Study to Evaluate the Safety and Tolerability of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Hypertension Associated With Interstitial Lung DiseaseCompletedNCT05176951Phase 2
- Validation of Patient Reported Outcome Measures in Participants With Nontuberculous Mycobacterial Lung Infection Caused by Mycobacterium Avium ComplexCompletedNCT04677543Phase 3
- A Study to Assess the Relative Bioavailability of Brensocatib Pediatric Oral Solution to Oral Tablets in Healthy ParticipantsCompletedNCT06344728Phase 1
- Single Dose Escalation Study of TR02 (Sustained Lipid Inhalation Technology [SLIT™] Amikacin) in Participants With Cystic Fibrosis (CF) Having Chronic Infections of Pseudomonas AeruginosaCompletedNCT06238856Phase 1
- A Study of the Palatability and Acceptability of Different Brensocatib Oral Liquid Formulations in Healthy ParticipantsCompletedNCT06178783Phase 1
- A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of C16TR for Inhalation With Tyvaso® Cohort in Healthy ParticipantsCompletedNCT06193031Phase 1
- A Study to Investigate Effect of Clarithromycin, a Strong CYP3A4 Inhibitor, on Brensocatib Pharmacokinetics in Healthy ParticipantsCompletedNCT05965570Phase 1
- A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder (TPIP) in Healthy ParticipantsCompletedNCT06091579Phase 1
- A Study of Treprostinil Palmitil Inhalation Powder (TPIP) In Pulmonary Arterial Hypertension (PAH)TerminatedNCT04791514Phase 2
- A Study to Assess Pharmacokinetics (PK) of Brensocatib Alone and With Multiple Doses of Rifampin or Esomeprozole in Healthy ParticipantsCompletedNCT05826574Phase 1
- A Study to Investigate Lung Deposition of Inhaled Amikacin-loaded Liposomes in Healthy Male ParticipantsCompletedNCT05999942Phase 1
- A Study to Evaluate the Pharmacokinetics (PK) and Safety of a Single Dose of Brensocatib in Participants With Normal Hepatic Function and Participants With Hepatic ImpairmentCompletedNCT05517525Phase 1
- A Study of the Safety, Pharmacokinetics, and Pharmacodynamics of INS1007 in Healthy Japanese and Caucasian ParticipantsCompletedNCT05927597Phase 1
- A Study of Brensocatib Following a Single Oral Administration in Participants With or Without Renal ImpairmentCompletedNCT05673603Phase 1
- A Study to Investigate the Effects of Brensocatib on QT Interval in Healthy ParticipantsCompletedNCT05355935Phase 1
- Assessment of INS1007 in Participants With Non-Cystic Fibrosis BronchiectasisCompletedNCT03218917Phase 2
- A Study of the Absorption, Metabolism, and Excretion of [14C]-Brensocatib Following a Single Oral Administration in Healthy Male ParticipantsCompletedNCT05652257Phase 1
- Safety and Efficacy Study of Recombinant Human Insulin-Like Growth Factor-I/Recombinant Human Insulin-Like Growth Factor Binding Protein-3 (rhIGF-I/rhIGFBP-3) In Myotonic Dystrophy Type 1CompletedNCT00577577Phase 2
- Multidose Safety and Tolerability Study of Dose Escalation of Liposomal Amikacin for Inhalation (ARIKACE™)CompletedNCT00777296Phase 1/2
- Study of Dose Escalation of Liposomal Amikacin for Inhalation (ARIKAYCE™) - Extension PhaseCompletedNCT03905642Phase 2
- Extension Study of Liposomal Amikacin for Inhalation in Cystic Fibrosis (CF) Patients With Chronic Pseudomonas Aeruginosa (Pa) InfectionCompletedNCT01316276Phase 3
- Study to Evaluate Arikayce™ in CF Patients With Chronic Pseudomonas Aeruginosa InfectionsCompletedNCT01315678Phase 3
- Study to Evaluate Efficacy of LAI When Added to Multi-drug Regimen Compared to Multi-drug Regimen AloneCompletedNCT02344004Phase 3
- Open-label Safety Extension Study Assessing Safety and Tolerability of LAI in Patients Who Participated in Study INS-212CompletedNCT02628600Phase 3
- Liposomal Amikacin for Inhalation (LAI) for Nontuberculous MycobacteriaCompletedNCT01315236Phase 2
- Safety and Tolerability Study of 2 Dose Level of Arikayce™ in Patients With Bronchiectasis and Chronic Infection Due to Pseudomonas Aeruginosa.CompletedNCT00775138Phase 2
- Safety/Tolerability Study of Arikayce™ in Cystic Fibrosis Patients With Chronic Infection Due to Pseudomonas AeruginosaCompletedNCT00558844Phase 1/2
- Study to Evaluate Arikace™ in CF Patients With Chronic Infection Due to Pseudomonas AeruginosaWithdrawnNCT01315691Phase 3
- Inhalation SLIT Cisplatin (Liposomal) for the Treatment of Osteosarcoma Metastatic to the LungCompletedNCT00102531Phase 1/2